Central serous chorioretinopathy in the fellow eye as a complication of intravitreal dexamethasone implant for the treatment of Irvine‐Gass syndrome

Georgalas, Ilias; Petrou, Petros; Pagoulatos, Dionysios; Papaconstantinou, Dimitris; Tservakis, Ioannis

doi:10.1111/cxo.12420

Cited by 8 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent literature review found only one case of IVTA causing new‐onset CSC, and another case of worsening pre‐existing CSC . Interestingly, a reported case of intravitreal Ozurdex implantation for refractory Irvine‐Gass syndrome was found to precipitate CSC in the fellow eye . One case presenting with bilateral multifocal serous retinal detachments initially diagnosed as Vogt‐Koyanagi‐Harada syndrome received high‐dose oral steroids and IVTA.…”

Section: Complications Of Ocular and Periocular Steroid Deliverymentioning

confidence: 99%

Local delivery of corticosteroids in clinical ophthalmology: A review

Fung

Tran

Lim

et al. 2020

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Locally administered steroids have a long history in ophthalmology for the treatment of inflammatory conditions. Anterior segment conditions tend to be treated with topical steroids whilst posterior segment conditions generally require periocular, intravitreal or systemic administration for penetration. Over recent decades, the clinical applications of periocular steroid delivery have expanded to a wide range of conditions including macular oedema from retino-vascular conditions. Formulations have been developed with the aim to provide practical, targeted, longer-term and more efficacious therapy whilst minimizing side effects. Herein, we provide a comprehensive overview of the

show abstract

Section: Complications Of Ocular and Periocular Steroid Deliverymentioning

confidence: 99%

Local delivery of corticosteroids in clinical ophthalmology: A review

Fung

Tran

Lim

et al. 2020

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…They suggested that their patient might have an idiosyncratic response to a low plasma concentration of dexamethasone or had a higher plasma concentration. 16 Recently, Eris et al reported a case of CSC after a single intravitreal dexamethasone implantation for diabetic macular edema. However, their report did not present medical history about absence or presence of previous intravitreal administrations and OCT scans of before and after intravitreal dexamethasone implantation were not in same location.…”

Section: Discussionmentioning

confidence: 99%

Development of Pachychoroid Pigment Epitheliopathy and Transformation to Central Serous Chorioretinopathy After Intravitreal Dexamethasone Implantation

Ersöz¹,

Hocaoğlu²,

Muslubaş³

et al. 2021

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

Purpose: To report first case of sequential development of pachychoroid pigment epitheliopathy (PPE) and central serous chorioretinopathy (CSC) after repeated intravitreal dexamethasone implantations for diabetic macular edema treatment. Methods: We present a case of a 54-year-old man having intravitreal dexamethasone implant for bilateral diabetic macular edema. Results: We observed development of pachychoroid pigment epitheliopathy, seen as a small pigment epithelial detachment on optical coherence tomography after a fourth dexamethasone implantation. A fifth implantation caused transformation of pachychoroid pigment epitheliopathy to central serous chorioretinopathy. Conclusion: Consecutive administration of dexamethasone implants may have a cumulative effect on retinal pigment epithelium, Bruch membrane, and choroid.

show abstract

“…Their patient was treated with an Ozurdex IVI for postoperative cystoid macular oedema and developed a central serous retinal detachment 14 days after the second injection. The patient showed spontaneous improvement after 4 months 1 . In 2017, Eris et al reported similar findings in a diabetic patient treated with Ozurdex IVIs for diabetic macular oedema in both eyes.…”

mentioning

confidence: 87%